Literature DB >> 18785245

Parkinsonism and dystonia caused by the illicit use of ephedrone--a longitudinal study.

Marianna Selikhova1, Ljuda Fedoryshyn, Yuri Matviyenko, Irena Komnatska, Marianna Kyrylchuk, Lesrek Krolicki, Andrzej Friedman, Andrew Taylor, H Rolf Jäger, Andrew Lees, Yanush Sanotsky.   

Abstract

A neurological syndrome characterized by levodopa unresponsive bradykinesia, retropulsion with falls backwards, dysarthria, gait disturbance, dystonia, and emotional lability was identified in 13 male opiate addicts following the prolonged intravenous use of ephedrone (methcathinone), a central nervous stimulant prepared from pseudoephedrine, potassium permanganate, and vinegar. The natural history, response to treatment, and clinical features has been studied, and MR and dopamine transporter SPECT brain imaging were carried out. Pubic hair was sampled for manganese. The clinical and radiological picture closely resembled previous reports of chronic manganese poisoning and increased mean manganese level in pubic hair observed for at least 1 year after cessation of ephedrone. Odor identification was intact. Cognitive assessment showed a mild executive dysfunction and a mild depression. DaTSCANs were all normal. The neurological syndrome bears some similarities to PSP but differs from Parkinson's disease. Delayed neurological progression despite discontinuation of ephedrone occurred in one-third of cases. Ephedrone poisoning should be considered as a possible cause of secondary Parkinsonism in young adults, particularly from Eastern Europe.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18785245     DOI: 10.1002/mds.22290

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  28 in total

1.  Mechanisms of lead and manganese neurotoxicity.

Authors:  April P Neal; Tomas R Guilarte
Journal:  Toxicol Res (Camb)       Date:  2013-03-01       Impact factor: 3.524

2.  White matter abnormalities in methcathinone abusers with an extrapyramidal syndrome.

Authors:  Ainars Stepens; Charlotte Jane Stagg; Ardis Platkajis; Marie-Hélène Boudrias; Heidi Johansen-Berg; Michael Donaghy
Journal:  Brain       Date:  2010-10-29       Impact factor: 13.501

3.  Brain deposition and neurotoxicity of manganese in adult mice exposed via the drinking water.

Authors:  Saritha Krishna; Celia A Dodd; Shahryar K Hekmatyar; Nikolay M Filipov
Journal:  Arch Toxicol       Date:  2013-07-06       Impact factor: 5.153

Review 4.  Manganese and its role in Parkinson's disease: from transport to neuropathology.

Authors:  Michael Aschner; Keith M Erikson; Elena Herrero Hernández; Elena Herrero Hernández; Ronald Tjalkens
Journal:  Neuromolecular Med       Date:  2009       Impact factor: 3.843

5.  Improvement in Ephedrone Parkinsonism After Global Pallidus Pars Interna Deep Brain Stimulation Implantation.

Authors:  Dariusz Koziorowski; Stanislaw Szlufik; Tomasz Mandat; Maria Kloda; Karolina Duszynska-Was; Agnieszka Drzewinska; Andrzej Friedman
Journal:  Mov Disord Clin Pract       Date:  2015-11-14

6.  A distinct variant of mixed dysarthria reflects parkinsonism and dystonia due to ephedrone abuse.

Authors:  Jan Rusz; Marika Megrelishvili; Cecilia Bonnet; Michael Okujava; Hana Brožová; Irine Khatiashvili; Madona Sekhniashvili; Marina Janelidze; Eduardo Tolosa; Evžen Růžička
Journal:  J Neural Transm (Vienna)       Date:  2014-01-21       Impact factor: 3.575

7.  Increased reflection impulsivity in patients with ephedrone-induced Parkinsonism.

Authors:  Atbin Djamshidian; Yanosh Sanotsky; Yuriy Matviyenko; Sean S O'Sullivan; Stephen Sharman; Marianna Selikhova; Ludmyla Fedoryshyn; Yuriy Filts; Jenny Bearn; Andrew J Lees; Bruno B Averbeck
Journal:  Addiction       Date:  2013-02-11       Impact factor: 6.526

Review 8.  Manganese and Parkinson's disease: a critical review and new findings.

Authors:  Tomás R Guilarte
Journal:  Environ Health Perspect       Date:  2010-04-19       Impact factor: 9.031

9.  Manganese-Induced Parkinsonism due to Ephedrone Abuse.

Authors:  Katrin Sikk; Sulev Haldre; Sten-Magnus Aquilonius; Pille Taba
Journal:  Parkinsons Dis       Date:  2011-02-17

Review 10.  T1 hyperintensity on brain imaging subsequent to gadolinium-based contrast agent administration: what do we know about intracranial gadolinium deposition?

Authors:  Nigel Hoggard; Giles H Roditi
Journal:  Br J Radiol       Date:  2016-10-19       Impact factor: 3.039

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.